Table 1 Clinical characteristics of the patients with axial spondyloarthritis and healthy controls
From: S100A4 is elevated in axial spondyloarthritis: a potential link to disease severity
nr-axSpA (n = 21) | AS I (n = 17) | AS II (n = 20) | Healthy controls (n = 40) | ||
|---|---|---|---|---|---|
Age (years) | median [IQR] | 30.6 [28.6–40.7] | 31.6 [27.2–37.3] | 37.3 [32.6–40.8] | 34.3 [30.1–38.6] |
Sex (male gender) | N (%) | 11 (52) | 15 (88) | 16 (80) | 31 (72) |
Disease durationa (years) | median [IQR] | 0.1 [0.0–5.0] | 3.0 [0.7–6.0] | 4.7 [3.8–9.0] | – |
BASDAI (units NRS) | median [IQR] | 4.8 [1.6–5.7] | 7.1 [4.4–8.0] | 4.5 [2.7–5.7] | – |
HLA-B27 (+) | N (%) | 21 (100) | 14 (82) | 16 (80) | – |
CRP, mg/L | median [IQR] | 3.2 [2.4–5.2] | 6.4 [5.4–7.3] | 4.5 [3.6–5.1] | – |
Uveitis (+) | N (%) | 9 (43) | 6 (35) | 8 (40) | – |
Psoriasis (+) | N (%) | 0 (0) | 0 (0) | 0 (0) | – |
Enthesitis (+) | N (%) | 13 (62) | 1 (6) | 7 (35) | – |
IBD (+) | N (%) | 1 (5) | 0 (0) | 0 (0) | – |
Peripheral arthritis (+) | N (%) | 18 (86) | 10 (59) | 15 (75) | – |
NSAIDs | N (%) | 15 (71) | 13 (77) | 9 (45) | – |
csDMARDs | N (%) | 6 (29) | 3 (18) | 0 (0) | – |
TNF inhibitors | N (%) | 0 (0) | 1 (6) | 11 (55) | – |